Display options
Cite
Banna GL, Cantale O, Friedlaender A, et al. Risk of SARS-CoV2-related mortality in non-small cell lung cancer patients treated with first-line immunotherapy alone or in combination with chemotherapy. Cancer Invest. 2021;1-12doi: 10.1080/07357907.2021.1970761.
Banna, G. L., Cantale, O., Friedlaender, A., Yusof, H., Acharige, S., & Alfredo, A. (2021). Risk of SARS-CoV2-related mortality in non-small cell lung cancer patients treated with first-line immunotherapy alone or in combination with chemotherapy. Cancer investigation, 1-12. https://doi.org/10.1080/07357907.2021.1970761
Banna, Giuseppe Luigi, et al. "Risk of SARS-CoV2-related mortality in non-small cell lung cancer patients treated with first-line immunotherapy alone or in combination with chemotherapy." Cancer investigation vol. (2021): 1-12. doi: https://doi.org/10.1080/07357907.2021.1970761
Banna GL, Cantale O, Friedlaender A, Yusof H, Acharige S, Alfredo A. Risk of SARS-CoV2-related mortality in non-small cell lung cancer patients treated with first-line immunotherapy alone or in combination with chemotherapy. Cancer Invest. 2021 Aug 19;1-12. doi: 10.1080/07357907.2021.1970761. Epub 2021 Aug 19. PMID: 34409906.
Copy Download .nbib Format: NLM
Share it on

Cancer Invest. 2021 Aug 19;1-12. doi: 10.1080/07357907.2021.1970761. Epub 2021 Aug 19.

Risk of SARS-CoV2-related mortality in non-small cell lung cancer patients treated with first-line immunotherapy alone or in combination with chemotherapy.

Cancer investigation

Giuseppe Luigi Banna, Ornella Cantale, Alex Friedlaender, Harliana Yusof, Shyamika Acharige, Addeo Alfredo

Affiliations

  1. Department of Oncology, Queen Alexandra University Hospital, Portsmouth Hospitals NHS Trust, United Kingdom.
  2. Department of Experimental Oncology, Mediterranean Institute of Oncology (IOM), Catania, Italy.
  3. Oncology Department, Geneva University Hospital, Geneva, Switzerland.

PMID: 34409906 DOI: 10.1080/07357907.2021.1970761

Abstract

BACKGROUND: The impact of systemic anticancer treatments on SARS-CoV-2-related mortality is still debatable.

METHODS: By a retrospective analysis of patients with non-small-cell lung cancer (NSCLC) treated with first-line Pembrolizumab or in combination with chemotherapy (ChT) during the first surge of the pandemic.

RESULTS: The adjusted risk of death was higher in patients treated with ChT + Pembrolizumab (HR 4.6, 1.2-17.4, p = 0.02). The SARS-CoV-2-related mortality rate was higher in patients treated with ChT + Pembrolizumab (p = 0.03), ≥70 years (p = 0.03) and current smokers (p = 0.17).

CONCLUSIONS: The addition of ChT to immunotherapy could be associated with increased risk of mortality and higher SARS-CoV-2-related mortality rate.

Keywords: SARS-CoV-2; immunotherapy; lung cancer; mortality; neutrophil-to-lymphocyte ratio (NLR)

Publication Types